BioDelivery Sciences International Stock News

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is how Hepion Pharmaceuticals, Inc. (HEPA) and BioDelivery Sciences International (BDSI) have performed compared to their sector so far this year.

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 2.53% and 16.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st

SA readers graivated to extremes last week, looking at both smaller newsmakers and megacap safe havens. They added ISPO, HOOK, GOOGL and AAPL. Also, they dropped BDSI after a merger deal.

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -35.29% and 90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

– BDSI Acquisition Expected to Close Late Q1 2022 –

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults

The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

On Precision BioSciences' (DTIL) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline.

NEW ORLEANS , Feb. 16, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) to Collegium Pharmaceutical, Inc. (NASDAQ: COLL ). Under the terms of the proposed transaction, shareholders of BioDelivery will receive only $5.60 in cash for each share of BioDelivery that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. … Full story available on Benzinga.com